ERCC1 gene is a useful independent prognostic tumor marker in patients with early stage non-small-cell lung cancer.

the ERCC1 C8092A polymorphism may have a role in progression of non-small cell lung cancer

variant genotypes of the rs3212948 C allele were associated with significantly decreased risk of lung cancer

ERCC1 expression was identified as a positive prognostic marker in resected non-small cell lung cancer

Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients.

loss of ERCC1 and class III beta-tubulin protein expression were predictors of better survival in non-small-cell lung cancer patients who received a platinum-based plus taxane chemotherapy.

study identified 2 functional variants in the ERCC1 5'-flanking region, -433T>C & 262G>T, which cooperatively influence transcriptional regulation of ERCC1; the -433C & 262G alleles are associated with susceptibility to lung cancer

ERCC1 overexpression is associated with resistance to platinum based chemotherapy in patients with nonsmall-cell lung cancer

High ERCC1 expression was associated with drug resistance to platinum-based chemotherapy in non-small-cell lung cancer.

high expression is an independent prognostic factor for poor overall survival in advanced non-small cell lung cancer patients

platinum-based chemotherapy affects the expression of tissue marker (ERCC1)in lung cancer

The ERCC1 C8092A polymorphism may influence the non-small cell lung cancer prognosis regardless of the ERCC1 protein expression and platinum sensitivity.

ERCC1 gene polymorphisms is associated with favorable clinical outcome in advanced non-small-cell lung cancer.

tumor ERCC1 expression is associated with tumor response and patient's survival in Chinese advanced non-small-cell lung cancer patients treated with platinum compounds.

Intratumoral ERCC1 mRNA expression is an independent predictive marker for survival of the patients with non-small cell lung cancer receiving platinum-based chemotherapy.

overexpression of ERCC1 is associated with brain and adrenal metastases in non-small cell lung cancer.

mRNA expression predicts overall survival in patients with non-small cell lung cancer who received neoadjuvant cisplatin-based chemotherapy

Study aimed to investigate the association between the ERCC2 751, 312 and ERCC1 118 polymorphisms and the risk of lung adenocarcinoma in Chinese non-smoking females.

Genetic polymorphisms in ERCC1 and XRCC1 genes might be prognostic factors in non-smoking female patients with lung adenocarcinoma.

Two polymorphisms, C8092A and C118T, affected the prognosis of non-small-cell lung cancer patients who received adjuvant and/or neoadjuvant platinum-based chemotherapy.

Compared with their parental cells, the expressions of CDA, RRM1, PTEN and ERCC1 increase in human gemcitabine-resistant non-small cell lung cancer cell lines.

High ERCC1 is associated with non-small-cell lung cancer.

results suggest that polymorphism Asn118Asn in ERCC1, A67T in iASPP and Asn148Glu in APE1 may associated with early onset of lung cancer as well as some specific subtype of lung cancer

ERCC1, RRM1 and BRCA1 are promising predictive and prognostic biomarkers in advanced non-small cell lung cancer.

The results suggest ERCC1 and PKCalpha might be correlated with the development of NSCLC. ERCC1 might be related to prognosis of non-small cell lung cancer.

The results suggest that there is no association between polymorphisms in ERCC1 C8092A and codon118 and response in patients with advanced non-small cell lung cancer receiving cisplatin-based chemotherapy.

Neoadjuvant chemotherapy can induce ERCC1 expression in elderly patients with non-small cell lung cancer.

Study suggests that ERCC1 polymorphisms and haplotypes do not play a role in lung and H&N cancer susceptibility in Caucasians.

non-small cell lung cancer specimens harboring EGFR activating mutations are more likely to express low ERCC1 mRNA levels.

An elevated expression of ERCC1 is an important factor for cisplatin insensitivity in non-small cell lung cancer.

genetic polymorphisms is not a prognostic predictor of platinum-based chemotherapy outcomes in non-small cell lung cancer

Tanshinone IIA acts via p38 MAPK to induce apoptosis and the down-regulation of ERCC1 and lung-resistance protein in cisplatin-resistant ovarian cancer.

low expression correlates with better response to chemotherapy and longer survival in patients with advanced non small-cell lung cancer

Harboring at least one 19007C allele may have protective effect in non-small cell lung cancer.

In stage III non-small cell lung cancer, ERCC1 DNA amplification and mRNA expression levels were higher, but protein overexpression was lower, than stage II and I.

The level of ERCC1 expression in tumors is a strong predictor of survival in resected non small cell lung carcinoma patients untreated without pre- or post-operative chemotherapy and/or radiotherapy.

data suggest that common genetic variations in ERCC1 may influence increased risk of smoking-related lung cancer and one of the causative effectors may locate around or within ERCC2

ERCC1 gene polymorphism is not associated with chemotherapy-induced neutropenia non-small-cell lung cancer.

ERCC1-negative non-small-cell lung cancer (NSCLC) had a higher rate of genomic abnormalities vs ERCC1-positive tumors; ERCC1-positive tumors seemed to share a common DNA damage response (DDR) phenotype with the overexpression of seven genes linked to DDR

Non-small cell lung cancer patients with up-regulated ERCC1 expression have a poor survival rate.

expression of excision repair cross-complementation group 1 (ERCC1) is correlated with a favourable prognosis in patients who have undergone surgical resection of non-small cell lung cancer.

Data found little evidence of an association between the T1900C or C8092A polymorphisms of ERCC 1 and the risk of lung cancer in Caucasian or Han Chinese people.

Current evidence suggests high ERCC1 may adversely influence survival and response in platinum-treated non-small cell lung cancer patients.

Data suggest that in non-small cell lung cancer (NSCLC) cells, ERCC1 is induced by etoposide through the p38 MAPK pathway, and this phenomenon is required for NSCLC survival and resistant DNA damage.

FISH-positive EGFR expression is associated with gender and smoking status, but not correlated with the expression of ERCC1 and BRCA1 proteins in non-small cell lung cancer.

High ERCC1 levels were associated with shorter survival and lower response to chemotherapy in advanced non-small cell lung cancer patients received palliative chemotherapy. [Meta-analysis]

High expression of ERCC-1 is associated with metastatic lymph nodes of patients with non-small cell lung cancer adenocarcinoma.

The expression of RRMI and ERCC1 genes in tumor tissues and RRM1 in peripheral blood lymphocytes is closely correlated with the response to chemotherapy and prognosis of patients with advanced non-small cell lung cancer.

Collectively, these data suggest that there is a synergistic relationship between PARP inhibition and low ERCC1 expression in NSCLC that could be exploited for novel therapeutic approaches in lung cancer therapy based on tumor ERCC1 expression.

Low ERCC1 expression was associated with longer overall survival in patients with pulmonary adenocarcinoma who were treated with pemetrexed/cisplatin as first-line chemotherapy.

ERCC1 C118T polymorphisms may serve as a biomarker for lung cancer risk and have prognostic value in patients with advanced non-small cell lung cancer (NSCLC) undergoing platinum-based treatment.

19q13-ERCC1 gene copy number increase is associated with non--small-cell lung cancer

The mRNA expression level of STMN1, TOP2A and ERCC1 are correlated with non-small cell lung carcinoma pathology type in Chinese patients.

Haplotype ERCC1 rs3212980 polymorphism is associated with lung cancer risk.

meta-analysis suggested that the ERCC1 C118T, ERCC2 Asp312Asn, and Lys751Gln may be useful biomarkers to predict the clinical outcomes of the platinum-based chemotherapy in non-small cell lung cancer patients

patients carrying the ERCC1 rs3212986 AA genotype were significantly associated with increased risk of death from non-small cell lung cancer when compared with those with CC genotype as a reference variable

Our results suggest that ERCC1 and BRCA1 mRNA expressions are associated with progression-free survival and overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy.

High ERCC1 expression is associated with non-small cell lung cancer.

ERCC1 rs3212948 G>C is a lung cancer risk-associated polymorphism.

ERCC1 rs11615 and rs3212986 polymorphisms may be helpful for designing individualized cancer treatment for non-small cell lung cancer patients

ERCC1 protein expression might play an important role in the prognosis of locally advanced stage III non-small cell lung cancer patients treated with cisplatin-based adjuvant chemotherapy.

Genetic polymorphism of ERCC1 correlated with response to platinum-based chemotherapy in non-small cell lung cancer Chinese patients.

This meta-analysis suggests that the ERCC1 19007T>C polymorphism may be associated with lung cancer risk in Asians

Advanced non-small cell lung cancer patients with both apurinic/apyrimidinic endonuclease 1 - and ERCC1 negative tumors had higher response rate to platinum-paclitaxel chemotherapy , longer progression-free survival and overall survival.

Data show that excision repair cross-complementation group 1 (ERCC1) rs11615 and rs3212986 polymorphisms were associated with poor response to chemotherapy and shorter survival time of advanced non-small cell lung cancer (NSCLC).

Analysis indicated that positive/high ERCC1 expression was associated with unfavorable overall survival suggesting it as a prognostic factor in cell lung cancer patients receiving platinum-based chemotherapy.

it is confirmed that ERCC1 is a chemotherapy-tolerating gene and a promising predictor in tailoring chemotherapy of non-small cell lung cancer

Results show that low ERCC1 mRNA expression was associated with better response to chemotherapy and correlated with longer survival in advanced non-small cell lung cancer Chinese patients treated with platinum-based chemotherapy.

we evaluated the association of gene polymorphisms, including the repair genes of XRCC1, ERCC1, ERCC2 (XPD), and TP53, with RFS in patients with non-small cell lung cancer

ERCC1 expression was a prognostic factor and predictive marker in non-small cell lung cancer , and gastric cancer after surgery alone, but was not a prognostic factor in breast cancer.[review]

our study found that ERCC1 rs11615 polymorphism can influence the chemotherapy response and overall survival of non-small cell lung cancer patients receiving cisplatin-based chemotherapy.

this study showed that ERCC1 rs2298881C>A could predict the survival outcomes of patients with surgically resected early stage Non-Small Cell lung cancer.

ERCC1/2 SNP, predict radiation dose-response and potentially guide personalized radiotherapy in non-small cell lung cancer.

study finds that ERCC1 and RRM1 are not independent prognostic factors of recurrence in stage I non-small cell lung cancer patients

Identification of ERCC1 expression level of tumor tissues in non-small cell lung cancer patients before treatment was not useful in prediction of treatment response and prognosis.

Evidence strongly indicated the prospect of ERCC1 C118T and C8092A as predictive biomarkers for platinum-based chemotherapy in Asian non-small cell lung cancer patients.

the present results indicate that the EGFR mutation status and TS and ERCC1 expression can be used as the predictors of overall survival after subsequent second-line treatments for adenocarcinoma non-small-cell lung cancer

a combination of ERCC1 and ERCC2 polymorphisms may predict overall survival among pemetrexed/platinum treated advanced non-squamous non-small-cell lung cancer patients

NDRG1 disruption alleviates cisplatin/sodium glycididazole-induced DNA damage response and apoptosis in ERCC1-defective lung cancer cells

Patients with advanced non-small cell lung cancer (NSCLC) displaying low expression of excision repair cross-complementation group 1 (ERCC1) benefit from cisplatin-based chemotherapy. High expression of ERCC1 indicates better progression-free survival in the treatment with erlotinib/bevacizumab supporting the prognostic impact.

expression not predictive of survival in locally advanced non-small cell lung cancer

Studied role of zinc finger protein 326 (ZNF326) in promotion of excision repair cross-complementation group 1 (ERCC1) expression in non-small cell lung cancer (NSCLC) cells.

ERCC1 C8092A (rs3213986) in 3'UTR of ERCC1 was associated with an increased risk of lung cancer, especially in smoking population, and therefore could be used as a valuable tumor marker.

PARP inhibition enhances tumor cell-intrinsic immunity in ERCC1-deficient non-small cell lung cancer.

The triplet combination might be effective for patients with advanced, untreated non-small cell lung cancer (NSCLC) overexpressing ERCC1. ERCC1 messenger RNA levels may be a predictive factor for response to platinum-containing regimens

ERCC1 polymorphisms may affect non-small cell lung cancer risk in the Polish population.

ERCC1 expression in lung adenocarcinoma is a useful prognostic marker and moreover, a useful predictive marker in patients receiving chemotherapy based on platinum in all stages of the disease

EGFR exon 19-deletion aberrantly regulate ERCC1 expression that may partly impaired DNA damage repair ability in non-small cell lung cancer.

The Significant Interaction of Excision Repair Cross-complementing Group 1 Genotypes and Smoking to lung cancer Risk.

ERCC1 Is a Predictive Biomarker for Non-small Cell lung cancer But Is Antibody-dependent.